Syndax Pharmaceuticals (SNDX) Interest & Investment Income (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Interest & Investment Income of $3.6 million for Q1 2026, down 50.42% year-over-year from $7.2 million in Q1 2025, and down 17.72% quarter-over-quarter from $4.3 million in Q4 2025.
Powered by 
Analysis
Syndax Pharmaceuticals (SNDX) Interest & Investment Income (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Interest & Investment Income history runs 12 years deep, the most recent figure standing at $3.6 million for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 50.42% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $12.9 million (down 34.34% YoY), while the FY2025 annual figure was $22.7 million, down 12.88% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $3.6 million, down from $4.3 million in the prior quarter.
- The five-year high for Interest & Investment Income was $20.8 million in Q4 2023, with the low at -$974000.0 in Q1 2024.
- The 5-year median for Interest & Investment Income is $3.6 million (2026), against an average of $3.9 million.
- Peak annual rise in Interest & Investment Income reached 8165.93% in 2022, while the deepest fall reached 8787.5% in 2022.
- Syndax Pharmaceuticals' Interest & Investment Income stood at $7.5 million in 2022, then soared by 176.68% to $20.8 million in 2023, then plunged by 65.85% to $7.1 million in 2024, then slumped by 39.11% to $4.3 million in 2025, then fell by 17.72% to $3.6 million in 2026.
- Business Quant data shows SNDX's Interest & Investment Income at $3.6 million in Q1 2026, $4.3 million in Q4 2025, and $5.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Syndax Pharmaceuticals | 1.84 Bn | 1.30 Bn | 60.67 Mn | 3.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.75 Mn |
| Mar 31, 2026 | -441,000.00 |
| Dec 31, 2025 | 4.33 Mn |
| Sep 30, 2025 | 5.27 Mn |
| Jun 30, 2025 | 5.95 Mn |
| Mar 31, 2025 | 364,000.00 |
| Dec 31, 2024 | 7.11 Mn |
| Sep 30, 2024 | 5.44 Mn |
| Jun 30, 2024 | -61,000.00 |
| Mar 31, 2024 | -974,000.00 |
| Dec 31, 2023 | 5.55 Mn |
| Sep 30, 2023 | 5.35 Mn |
| Jun 30, 2023 | -238,000.00 |
| Mar 31, 2023 | 470,000.00 |
| Dec 31, 2022 | 2.99 Mn |
| Sep 30, 2022 | 1.78 Mn |
| Jun 30, 2022 | -695,000.00 |
| Mar 31, 2022 | -685,000.00 |
| Dec 31, 2021 | 91,000.00 |
| Sep 30, 2021 | 83,000.00 |